Avidity Biosciences, Inc.
General ticker "RNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.9B (TTM average)
Avidity Biosciences, Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 1.1%: low 14.89$, high 16.48$
Factors to consider:
- Total employees count: 391 (+54.5%) as of 2024
- Top business risk factors: Need for additional capital, Limited operating history, Clinical trial success, Regulatory and compliance, Market competition
- Current price 58.0% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [36.80$, 95.94$]
- 2026-12-31 to 2027-12-31 estimated range: [21.79$, 61.76$]
Financial Metrics affecting the RNA estimates:
- Negative: with PPE of -14.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.55 <= 0.01
- Positive: Investing cash flow per share per price, % of -0.38 > -0.63
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 86.24 > 64.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term RNA quotes
Long-term RNA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $9.56MM | $10.90MM | $18.75MM |
| Operating Expenses | $245.16MM | $389.83MM | $764.70MM |
| Operating Income | $-235.60MM | $-378.94MM | $-745.94MM |
| Non-Operating Income | $23.38MM | $56.63MM | $61.31MM |
| R&D Expense | $190.97MM | $303.59MM | $559.16MM |
| Income(Loss) | $-212.22MM | $-322.30MM | $-684.63MM |
| Profit(Loss)* | $-212.22MM | $-322.30MM | $-684.63MM |
| Stockholders Equity | $500.76MM | $1,424.96MM | $1,688.60MM |
| Assets | $628.55MM | $1,563.89MM | $1,958.05MM |
| Operating Cash Flow | $-119.06MM | $-300.87MM | $-650.44MM |
| Capital expenditure | $4.23MM | $7.07MM | $13.32MM |
| Investing Cash Flow | $-130.07MM | $-854.20MM | $-38.03MM |
| Financing Cash Flow | $93.86MM | $1,192.36MM | $850.99MM |
| Earnings Per Share** | $-2.91 | $-2.89 | $-4.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.